NVOH Novo Nordisk A/S (B Shares) ADRhedged
ETF on NYSE (US) · Actively managed · Listing
Most notable sale · Novo Nordisk A/S
Novo Nordisk A/S cut by 11%
Shares went from 94,793 to 84,261 ($3.48M → $4.04M). Now 97.3% of the portfolio. Estimated trade $505K.
Largest holding: Novo Nordisk A/S, cut 11%, 84,261 shares ($4.04M).
| Current positions Top 3 | % of book |
|---|---|
| Novo Nordisk A/S NVO $4.04M · −11% sh | 97.3% |
| DREYFUS TRSRY SECURITIES $116K · −17% units | 2.8% |
| CANADIAN IMPERIAL BANK OF COMMERCE CSWAP DKK VS USD −$3.15K · unch. | <0.1% |
Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against Mar 31, 2026.
| Sectors | % of long value |
|---|---|
| Healthcare | 97.2% |
| Unclassified | 2.8% |
| Industries | % of long value |
|---|---|
| Drug Manufacturers - General | 97.2% |
| Unclassified | 2.8% |
| Initiations 0 | Value |
|---|---|
| None this period. | |
| Increases 0 | Change |
|---|---|
| None this period. | |
| Reductions 1 | Change |
|---|---|
| Novo Nordisk A/S NVO $3.48M → $4.04M | −11% |
| Terminations 0 | Change |
|---|---|
| None this period. | |
Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Jun 30, 2026 (Form N-PORT) vs the portfolio of Mar 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the prospectus filed Apr 29, 2026.
The Novo Nordisk A/S (B Shares) ADRhedged™ (the "Series") seeks to provide investment results that correspond generally, before fees and expenses, to the total return of the ordinary shares of Novo Nordisk A/S (B Shares) in its local market.
Principal investment strategies
The Series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts ("ADRs") of the Novo Nordisk A/S (B Shares) (the "Company"). The Series will not invest directly in the Company. ADRs are receipts, issued by an American bank or trust issuer, which evidence ownership of underlying securities issued by a non-U.S. issuer. Generally, ADRs, issued in registered form, are designed for use in the U.S. securities markets. The Series invests in the ADRs of the Company (the "Portfolio Securities") and a currency swap (the "Currency Hedge Contract") designed to hedge against fluctuations in the exchange rate between the U.S. dollar and the Danish krone ("Local Currency"). The Currency Hedge Contract is with a counterparty acting as principal. The notional value of the Currency Hedge Contract is adjusted daily based on the current value of the Portfolio Securities. Although ADRs are U.S. dollar denominated and traded on U.S. exchanges, they are still subject to currency risk because changes in foreign currency exchange rates affect their value. The Currency Hedge Contract is designed to minimize the impact of fluctuations in the exchange rate between the U.S. dollar and the Local Currency. The Currency Hedge Contract will be marked to market and settled daily based on the notional value of the Currency Hedge Contract as of the settlement time on a particular day and the change in the value of the Local Currency in relation to the U.S. dollar ("Exchange Rate") from the settlement time on the prior business day to the settlement time on the current business day. 168 Changes in rates of the Local Currency compared to the U.S. dollar may negatively affect the value of the Currency Hedge Contract. If as a result of a change in the value of the Local Currency relative to the U.S. dollar, the Currency Hedge Contract increases in value, the counterparty will pay the Series an amount in U.S. dollars equal to the increase in the value of the Currency Hedge Contract. If the Currency Hedge Contract decreases in value, the Series will pay the counterparty an amount in U.S. dollars equal to the decrease in the value of the Currency Hedge Contract. In order to obtain any necessary amount of cash, the Manager may sell Portfolio Securities. The Series will maintain amounts not invested in ADRs in cash or cash equivalents, including money market funds. The Currency Hedge Contract is subject to counterparty risk in that if the counterparty fails to make any payments, the Series could incur a loss. As a result of mark to market payments or otherwise, the ratio of Portfolio Securities to Shares will vary over time. For example, upon formation, a Series Share might be equal to one Share of the ADR. If the mark to market payments for the Currency Hedge Contract would require the Series to sell ADRs in order to make a payment to the counterparty, each Series Share would equal less than one Share of the ADR. As a result of the sales of an ADR, the net asset value of the Series and, correspondingly, the fractional amount of ADRs represented by each Share will decrease over the life of the Series. The Series does not seek to replicate the performance of a specified index. The Series is non-diversified and therefore may invest a greater percentage of its assets in a particular issuer than a diversified Series. Novo Nordisk A/S Novo Nordisk A/S a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Novo Nordisk A/S develops, produces, and markets pharmaceutical products. Novo Nordisk A/S focuses on diabetes care and offers insulin delivery systems and other diabetes products. Novo Nordisk A/S also works in areas such as hemostasis management, growth disorders, and hormone replacement therapy. Novo Nordisk A/S is registered under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Management and Contact
- Adviser
- Precidian Funds, LLC
- Portfolio managers
-
Daniel McCabe, Chief Executive Officer of the Manager, has served as the Series portfolio manager since inception.
Mark Criscitello, Founding Principal of the Manager, has served as the Series portfolio manager since inception.
- Phone
- (844) 954-5333
- Website
- adrhedged.com
Holdings as of Jun 30, 2026
The full portfolio as of the quarter end Jun 30, 2026, from the fund's report to the SEC (Form N-PORT, filed Aug 21, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of Mar 31, 2026.
3 lines, 1 linked, weights sum to 99.59% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| NOVO NORDISK A/S | NVO US6701002056 | Equity | 84,261 | −10,532 | 96.87% | $ 4.039M |
|
DREYFUS TRSRY SECURITIES
|
Money market | 116,462.78 | −24,315.79 | 2.79% | $ 116.463K | |
|
CANADIAN IMPERIAL BANK OF COMMERCE CSWAP DKK VS USD
|
Swap short | 1 | 0 | -0.08% | $ -3,154.93 |
Trades Mar 31, 2026 to Jun 30, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| NOVO NORDISK A/S | NVO | Sold | 94,793 | 84,261 | −10,532 | $ -504.904K |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up